n
(medicine) A protein from patients with Alzheimer's
n
(pharmacology) An antidiabetic drug C₂₅H₄₃NO₁₈ (trademark Precose) that is taken orally as a tablet in the treatment of type 2 diabetes. It is an oligosaccharide produced by fermentation of a bacterium (Actinoplanes utahensis). The drug slows the absorption of glucose in the small intestine by inhibiting enzymes that break down complex carbohydrates.
n
(pharmacology) An anti-inflammatory drug used to treat rheumatoid arthritis.
n
(pharmacology) A glucagon-like peptide-1 agonist drug under investigation for treatment of diabetes.
n
(pharmacology) A drug being developed to treat diabetes.
n
(pharmacology) An antidiabetic drug.
n
(medicine) Any drug that mimics the action of amylin; they are used to counter diabetes
n
(pharmacology) A pharmaceutical drug for the treatment of type 2 diabetes mellitus.
n
A recombinant methionyl human stem cell factor.
n
(pharmacology) An anticoagulant drug for the treatment of venous thromboembolic events.
n
An enzyme replacement therapy medication used for the treatment of glycogen storage disease type II (Pompe disease).
n
(pharmacology) A thiazolidinedione derivative that shows antihyperglycemic activity.
n
A monoclonal immunoglobulin light chain originally found in the urine, detection of which may be suggestive of multiple myeloma or Waldenström's macroglobulinemia.
n
Any of a class of antihyperglycemic and antimalarial drugs based upon this compound.
n
(medicine) Any of a group of drugs based on a biguanide
n
(pharmacology) An antidiabetic drug of the biguanide class.
n
(pharmacology) A drug C₂₄H₂₅FO₅S·½H₂O that lowers blood sugar by reducing the reabsorption of glucose from the kidneys and is taken orally to treat type 2 diabetes. It is marketed under the trademark Invokana and when used in combination with metformin, under the trademark Invokamet.
n
A particular immunostimulant drug.
n
(pharmacology) A particular antidiabetic drug.
n
An injectable gonadotropin-releasing hormone antagonist used to treat some hormone-sensitive cancers and gynaecological disorders.
n
(pharmacology) An antidiabetic drug.
n
(medicine) A sulfonylurea antidiabetic drug
n
(pharmacology) A particular thiazolidinedione.
n
(pharmacology) A synthetic molecule based on a peptide, under investigation for the treatment of glioblastoma by inhibiting angiogenesis.
n
A peptide drug for the treatment of diabetes
n
(pharmacology) A drug C₂₁H₂₅ClO₆·C₃H₈O₂·H₂O that lowers blood sugar by reducing the reabsorption of glucose from the kidneys and is taken orally to treat type 2 diabetes. It is marketed under the trademark Farxiga.
n
A synthetic form of erythropoietin, used to treat anemia.
n
(pharmacology) A thiazolidinedione drug used to treat metabolic disorders.
n
A medication used to treat severe hypoglycemia in people with diabetes.
n
(pharmacology) A particular antiobesity drug that is an amylinomimetic peptide.
n
Synonym of insulin degludec (in mentions where the full name is rendered superfluous by the context)
n
(pharmacology) A particular antidiabetic and protease inhibitor.
n
A drug that acts as a cholecystokinin antagonist.
n
(medicine) The antidiabetic drug "metformin hydrochloride"
n
Initialism of dipeptidyl peptidase 4., inhibitors of which are the gliptins
n
(pharmacology) An investigational glucagon-like peptide-1 receptor agonist.
n
(pharmacology) A particular gliptin drug.
n
(pharmacology) A pituitary drug.
n
(pharmacology) A drug used to treat Gaucher's disease, commonly used as the tartrate salt.
n
(pharmacology) An orally available competitive inhibitor of sodium–glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity.
n
(pharmacology) A hypoglycemic agent.
n
(pharmacology) An aldosterone antagonist used as an adjunct in the management of chronic heart failure.
n
(pharmacology) A particular gliflozin drug.
n
(pharmacology) An antidiabetic drug.
n
A drug used for the treatment of hyperparathyroidism
n
(pharmacology) A particular antidiabetic drug.
n
(pharmacology) Synthetic polypeptide exendin-4 that mimics the hormone incretin and is used for the treatment of diabetes.
n
A granulocyte colony-stimulating factor (G-CSF) analogue used to stimulate the proliferation and differentiation of granulocytes.
n
(pharmacology) A combretastatin phosphate, present in Combretum caffrum that has antineoplastic activity
n
(pharmacology) A drug C₁₅H₂₂O₃ that regulates blood serum lipids and is used especially to lower the levels of triglycerides and increase the levels of HDLs.
n
(pharmacology) A particular gliptin drug.
n
(pharmacology) Any of a class of drugs that are calcitonin gene-related peptide (CGRP) inhibitors used to treat migraine.
n
Alternative form of glargine
n
Ellipsis of insulin glargine. [(pharmacology) A long-acting recombinant form of insulin (trademark Lantus) administered by subcutaneous injection for the management of type 1 and type 2 diabetes.]
n
(pharmacology) An enzyme inhibitor.
n
(pharmacology) An oral sulfonylurea antidiabetic C₂₃H₂₈ClN₃O₅S (trademarks Diaβeta, Glycovance, Micronase) used similarly to glipizide.
n
(pharmacology) An antidiabetic sulfonylurea drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) A molecule with antidiabetic effects, resembling glibenclamide.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) A sulfonylurea antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) Any of a class of drugs that inhibit renal glucose reabsorption and therefore lower blood glucose.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) A sulfonylurea antidiabetic drug.
n
(pharmacology) Contraction of meglitinide. [(pharmacology) Any of a class of drugs used to treat type II diabetes.]
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) A sulfonylurea antidiabetic drug C₂₁H₂₇N₅O₄S (trademark Glucotrol) that lowers blood glucose levels and is used in the control of hyperglycemia associated with type 2 diabetes.
n
(pharmacology) Any of the class of dipeptidyl peptidase-4 inhibitors, a class of oral hypoglycemics that block DPP-4.
n
(pharmacology) A sulfonylurea antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) An antidiabetic sulfonylurea drug.
n
(pharmacology) Any of a class of drugs used to control diabetes.
n
(pharmacology) Synonym of thiazolidinedione.
n
Synonym of insulin glulisine (in mentions where the full name is rendered superfluous by the context)
n
(pharmacology) Alternative form of glibenclamide. [(pharmacology) An oral sulfonylurea antidiabetic C₂₃H₂₈ClN₃O₅S (trademarks Diaβeta, Glycovance, Micronase) used similarly to glipizide.]
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
(pharmacology) A sulfonylurea antidiabetic drug.
n
(pharmacology) An antidiabetic drug.
n
A trade name for insulin lispro.
n
A trade name for certain types of the drug insulin.
n
(pharmacology) A drug used to treat hyperglycemia.
n
A broad-spectrum matrix metalloproteinase inhibitor
n
A medication used in the treatment of Gaucher's disease, a recombinant DNA-produced analogue of human β-glucocerebrosidase.
n
Alternative form of imiquimod [A particular topical immune-response modifier.]
n
(medicine) A form of isophane insulin used to treat diabetes
n
Any exogenous preparation of this hormone for use as a medication.
n
Any of several molecular analogues of endogenous insulin with similar insulin receptor ligand activity but suitable for differing time spans of bioavailability and action; produced recombinantly and used as medications in treating diabetes; often metonymically just called insulin, the molecular modifications notwithstanding.
n
(pharmacology) A short-acting modified recombinant form of insulin (a short-acting insulin analogue) administered by subcutaneous injection in the treatment of type 1 and type 2 diabetes. Trade names (trademarks) include NovoLog, Fiasp, and others.
n
An ultralong-acting basal insulin analogue used to control diabetes.
n
(pharmacology) A long-acting recombinant form of insulin administered by subcutaneous injection in the treatment of type 1 and type 2 diabetes. Trade names include Levemir and possibly others.
n
(pharmacology) A long-acting recombinant form of insulin (trademark Lantus) administered by subcutaneous injection for the management of type 1 and type 2 diabetes.
n
(pharmacology) An insulin analog.
n
(pharmacology) A short-acting insulin analogue administered by injection in the treatment of type 1 and type 2 diabetes. Trade names include Humalog among others.
n
A compound that stimulates the release of insulin
n
(pharmacology) A particular gliflozin drug.
n
(uncountable, medicine) A synthetic form of insulin used to treat diabetes.
n
(pharmacology) A medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors.
n
A synthetic hormone used to stimulate the immune system.
n
An intermediate-acting form of insulin, between isophane and ultralente.
n
(pharmacology) A recombinant hirudin derived from yeast cells, used as an anticoagulant.
n
(pharmacology) A DPP-4 inhibitor developed for treatment of type II diabetes.
n
Alternative form of linagliptin [(pharmacology) A DPP-4 inhibitor developed for treatment of type II diabetes.]
n
A potent, irreversible inhibitor of pancreatic lipase, first isolated from the actinobacterium Streptomyces toxytricini.
n
(pharmacology) A antidiabetic drug C₁₇₂H₂₆₅N₄₃O₅₁ (trademark Victoza) that is an analog of glucagon-like peptide 1 administered by injection in the treatment of type 2 diabetes and obesity.
n
(pharmacology) A glucogan-like peptidase agonist being investigated for the treatment of diabetes.
n
(pharmacology) A particular thiazolidinedione antidiabetic drug.
n
(pharmacology) The thioglycoside 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol that is used to treat diabetes
n
A recombinant human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency
n
(pharmacology) A chemical compound which is the prototype of this drug class (see structure drawing).
n
(pharmacology) A biguanide derivative, C₄H₁₁N₅, used, now chiefly as the hydrochloride, as an oral hypoglycemic agent in the treatment of type 2 diabetes mellitus; 1,1-dimethylbiguanide.
n
(pharmacology) An antidiabetic drug C₈H₁₇NO₅ that is taken orally as a tablet in the treatment of type 2 diabetes and acts to slow the absorption of glucose in the small intestine by inhibiting enzymes that break down complex carbohydrates.
n
(pharmacology) A drug used primarily to treat certain kinds of Gaucher's disease by inhibiting glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.
n
A drug to treat diabetes.
n
A solution of two forms of insulin (fast-acting, and long-lasting)
n
(pharmacology) A peroxisome proliferator-activated receptor agonist.
n
Alternative form of nateglinide [(pharmacology) A meglitinide drug for the treatment of type II diabetes that lowers blood glucose by stimulating the release of insulin from the pancreas.]
n
(pharmacology) A meglitinide drug for the treatment of type II diabetes that lowers blood glucose by stimulating the release of insulin from the pancreas.
n
A niacin derivative used as a hypolipidemic agent.
n
(pharmacology) A monoclonal antibody used mainly in allergy-related asthma therapy with the purpose of reducing allergic hypersensitivity.
n
A medication high in glucose often given in a gel form to treat patients experiencing a diabetic crisis
n
A recombinant form of a material that stimulates the production of granulocytes (in cows)
n
A PEGylated form of filgrastim.
n
(chemistry) Used to indicate PEGylation in the names of monoclonal antibodies.
n
A growth hormone receptor antagonist used in the treatment of acromegaly.
n
(pharmacology) An antidiabetic drug of the biguanide class.
n
(pharmacology) A thiazolidinedione derivative taken orally in the form of its hydrochloride C₁₉H₂₀N₂O₃S·HCl to treat type 2 diabetes by decreasing insulin resistance.
n
(pharmacology) A synthetic amylin analog (trademark Symlin) that is administered by injection in the form of its acetate C₁₇₁H₂₆₇N₅₁O₅₃S₂·C₂H₄O₂ and is used with insulin therapy to lower blood sugar levels in patients with type 1 and type 2 diabetes.
n
(pharmacology) A drug used in chemotherapy, the ester formed from prednisolone and chlorambucil.
n
An esomeprazole tablet, taken to reduce stomach acidity.
n
(pharmacology) Synonym of remogliflozin etabonate.
n
(pharmacology) A drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis and type 2 diabetes.
n
(pharmacology) A meglitinide drug C₂₇H₃₆N₂O₄ (trademark Prandin) that stimulates insulin release and is taken orally to treat type 2 diabetes.
n
(biochemistry) A particular TLR4 signal inhibitor.
n
(pharmacology) A thiazolidinedione derivative used to treat diabetes.
n
A fusion protein analog of thrombopoietin.
n
(pharmacology) A thiazolidinedione derivative (trademark Avandia) taken orally in the form of its maleate C₁₈H₁₉N₃O₃S·C₄H₄O₄ to treat type 2 diabetes by decreasing insulin resistance.
n
Alternative form of rosiglitazone [(pharmacology) A thiazolidinedione derivative (trademark Avandia) taken orally in the form of its maleate C₁₈H₁₉N₃O₃S·C₄H₄O₄ to treat type 2 diabetes by decreasing insulin resistance.]
n
(pharmacology) A recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), produced in yeast, which functions as am immunostimulator, primarily used for myeloid reconstitution after bone marrow transplantation.
n
(pharmacology) A particular glitazar for the treatment of type 2 diabetes mellitus and dyslipidemia.
n
(pharmacology) A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze.
n
(pharmacology) A methylated cyclopeptide cyclo[N-methyl-ʟ-alanyl-ʟ-tyrosyl-ᴅ-tryptophyl-ʟ-lysyl-ʟ-valyl-ʟ-phenylalanyl] which inhibits growth hormone secretion.
n
(pharmacology) A peptide used in the treatment of diabetes.
n
(pharmacology) Synonym of sergliflozin etabonate.
n
(pharmacology) An investigational antidiabetic drug.
n
A phosphate-binding drug used to treat hyperphosphatemia in patients with chronic kidney disease.
n
(pharmacology) A synthetic peptide used in the drug lucinactant.
n
(pharmacology) A hypoglycemic drug taken orally in the form of its phosphate C₁₆H₁₅F₆N₅O·H₃PO₄·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Januvia and when used in combination with metformin, under the trademark Janumet.
n
(pharmacology) An antidiabetic drug.
n
An inhibitor of glucose transporters used as a drug to counter diabetes
n
(medicine) Any of a family of oligopeptides used as tachykinin antagonists
n
A particular gastrin receptor antagonist.
n
human recombinant FGF18, as a candidate drug to treat knee osteoarthritis
n
A naturally-occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals, used to treat certain cancers.
n
Any of a class of antidiabetic drugs that act by increasing insulin release from the beta cells in the pancreas; some are also used as herbicides.
n
(pharmacology) A pharmaceutical drug, a glucagon-like peptide-1 agonist, under investigation for treatment of type 2 diabetes.
n
(pharmacology) A particular therapeutic hormone.
n
(pharmacology) A particular gliptin drug used to treat type 2 diabetes mellitus.
n
(pharmacology) A peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.
n
(organic chemistry) Any of a class of drugs, used to treat diabetes, containing a five-membered heterocyclic ring containing a nitrogen and a sulfur atom and two carbonyl groups
n
Any of several commercial glitazones
n
A potent small molecule non-ATP-competitive GSK3 inhibitor that has been investigated as a potential treatment for Alzheimer's disease and paralysis supranuclear.
n
A medication for the treatment of type 2 diabetes.
n
(pharmacology) A particular gliflozin drug.
n
A sulfonylurea antidiabetic drug.
n
A drug that blocks potassium channels, used in the treatment of diabetes.
n
An aldose reductase inhibitor formerly used to treat certain diabetic complications.
n
(pharmacology) A pharmaceutical drug used for the treatment of diabetes mellitus.
n
(pharmacology) A thiazolidinedione derivative C₂₄H₂₇NO₅S formerly used to treat type 2 diabetes but now withdrawn from use because of its link to serious hepatic reactions.
n
Abbreviation of thiazolidinedione. [(organic chemistry) Any of a class of drugs, used to treat diabetes, containing a five-membered heterocyclic ring containing a nitrogen and a sulfur atom and two carbonyl groups]
n
A long-acting form of insulin.
n
(medicine) Any of a specific type of statins
n
(pharmacology) A particular antidiabetic drug.
n
Alternative form of vildagliptin [(pharmacology) A particular antidiabetic drug.]
n
An alpha glucosidase inhibitor used to lower blood glucose levels in diabetics.
Note: Concept clusters like the one above are an experimental OneLook
feature. We've grouped words and phrases into thousands of clusters
based on a statistical analysis of how they are used in writing. Some
of the words and concepts may be vulgar or offensive. The names of the
clusters were written automatically and may not precisely describe
every word within the cluster; furthermore, the clusters may be
missing some entries that you'd normally associate with their
names. Click on a word to look it up on OneLook.
Our daily word games Threepeat and Compound Your Joy are going strong. Bookmark and enjoy!
Today's secret word is 7 letters and means "Property or assets, excluding real estate." Can you find it?